Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy.

Mohan, Viswanathan; Schmider, Wolfgang; Singh, Kiran P; Rotthaeuser, Baerbel; Mukherjee, Bhaswati; Aravind, S R

Mohan, Viswanathan; Schmider, Wolfgang; Singh, Kiran P; Rotthaeuser, Baerbel; Mukherjee, Bhaswati; Aravind, S R.

Afiliación

Mohan V; MV Diabetes Specialities Centre, Madras Diabetes Research Foundation, Chennai, India.
Schmider W; Sanofi, Frankfurt, Germany, India.
Singh KP; Department of Endocrinology, Fortis Hospital Mohali, Chandigarh, India.
Rotthaeuser B; Sanofi, Frankfurt, Germany, India.
Mukherjee B; Sanofi, Paris, France, Europe.
Aravind SR; Diabetes Care and Research Center, Diacon Hospital, Bengaluru, Karnataka, India.

Indian J Endocrinol Metab ; 26(4): 354-361, 2022.

Article en En | MEDLINE | ID: mdl-36185965

Palabras clave

Biosimilar; SAR341402; insulin aspart mix; pharmacokinetics; premix; type 2 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Indian J Endocrinol Metab Año: 2022 Tipo del documento: Article País de afiliación: India Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google